CORESTEMCHEMON Inc. Logo

CORESTEMCHEMON Inc.

Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.

166480 | KO

Overview

Corporate Details

ISIN(s):
KR7166480004
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로255번길 24 (삼평동), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CORESTEMCHEMON Inc. is a biotechnology corporation operating through two primary divisions: Bio-pharmaceuticals and a Nonclinical Contract Research Organization (CRO). The Bio-pharmaceutical division focuses on developing novel stem cell therapies for intractable conditions, with clinical trials targeting neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), multiple sclerosis, and cerebellar ataxia, as well as autoimmune disorders such as systemic lupus erythematosus (SLE). The Nonclinical CRO division provides essential preclinical services, conducting toxicity and efficacy evaluations for a wide range of clients in the pharmaceutical, biopharmaceutical, medical device, and cosmetic industries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Share Issue/Capital Change
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean 8.6 KB
2025-09-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 38.9 KB
2025-09-16 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 291.4 KB
2025-09-16 00:00
Prospectus
투자설명서
Korean 3.3 MB
2025-09-16 00:00
Share Issue/Capital Change
권리락 (유상증자)
Korean 3.5 KB
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 44.4 KB
2025-09-08 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.5 MB
2025-09-01 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.8 MB
2025-08-18 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 35.4 KB
2025-08-18 00:00
Registration Form
증권신고서(지분증권) (2025.10)
Korean 3.2 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.0 MB
2025-08-08 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.4 MB
2025-07-28 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 21.4 KB
2025-07-21 00:00
Capital/Financing Update
교환사채(해외교환사채포함)발행후만기전사채취득 (제2회차)
Korean 9.9 KB
2025-07-21 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.8 KB

Automate Your Workflow. Get a real-time feed of all CORESTEMCHEMON Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CORESTEMCHEMON Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CORESTEMCHEMON Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IGC Pharma, Inc. Logo
Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.
United States of America
IGC
IL DONG PHARMACEUTICAL CO., LTD. Logo
Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.
South Korea
249420
ILSUNG IS CO., LTD. Logo
Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.
South Korea
003120
ILYANG PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.
South Korea
007570
I-Mab Logo
A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.
United States of America
IMAB
ImageneBio, Inc. Logo
A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.
United States of America
IMA
IM Cannabis Corp. Logo
International producer of medical-grade cannabis for patients and providers in Israel and Germany.
United States of America
IMCC
Immatics N.V. Logo
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America
IMTX
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America
IMMX
IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC

Talk to a Data Expert

Have a question? We'll get back to you promptly.